Figure 3. The combination of cetuximab with celecoxib improves the antitumor activity against Caco-2 tumor xenografts.

Male nude mice (NOD-SCID) were xenografted with Caco-2 colorectal carcinoma cells. When tumors reached approximately 100–150 mm³ volume, cetuximab (CTX, 20 mg/kg) and/or celecoxib (CXB, 60 mg/kg) were administered twice a week for 24 days. A. Relative tumor volume in the different treatment groups (*p <0.05, compared with the control; # p<0.05, compared with cetuximab-treated cells). B. Representative images of excised tumors.